tirzepatide higher dose trial Characteristics and Dosing Patterns of Users with Type 2 Diabetes in the United States | Diabetes Therapy Tirzepatide Dosage & Titration: Complete

In trials focusing on individuals with obesity, participants using this medication experienced an average weight loss of 15% to 24% over 72 weeks

published online, doi:10.1146/annurev-physiol-030212-183750 (5 November 2012)

The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications

Many people will pay I think between $500 and $1,000 even with insurance if their plan doesnt cover the drug

& Cevik, C

One important safety note: GLP-1s carry an FDA-boxed warning about the potential risk of thyroid C-cell tumors